DIHYDROPYRIDINE DERIVATIVES

Abstract: A dihydropyridine derivative has the preferred formula wherein R′₁ denotes methyl, chlorine, bromine, fluorine, tri­ fluoromethyl, nitro, cyano or methoxy, R₇ denotes benzyl; and the dihydropyridine links to the 2-,3-, or 4-position of the pyridine. The compound has an activity as a Ca-antagonist, and is useful for treating vascular disorders such as coronary artery disease, celebral artery disease, and hypertension.

Description: This invention relates to a novel 4-pyridyl-dihydropyridine derivative. More particularly, it is concerned with a 4-pyridyl-dihydropyridine derivative having an activity such as calcium-antagonism, blood pressure lowering and phosphodiesterase inhibition. Hitherto, a 4-phenyl-dihydropyridine-3,5-dicarboxylic acid ester has been known as having such activity (US-A-3644627). For example, 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester is commercially available as Nifedipine (The Merck Index, 10th Edition). An improvement in the water solubility of the dimethyl ester compound was made by changing at least one of the ester moieties to an N-substituted aminoalkyl ester (US-A-3985758), to provide compounds among which 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester is described as Nicardipine in the Merck Index. In an alternative range of compounds disclosed in DE-A-2218644, one of the abovementioned methyl ester moieties is replaced by a heteroalkylester moiety. Although it is already known that, because of the abovementioned activity, these compounds are useful as antihypertensive agents, vasodilators for peripheral and cerebral blood vessels, and curative agents for coronary artery disorders (angina pectoris), emergence of a dihydropyridine derivative having a more excellent effect is eagerly awaited. An object of this invention is to provide a dihydropyridine derivative and the innoxious salt thereof, which have a more excellent pharmacological activity. Another object of this invention is to provide a pharmaceutical composition comprising a dihydropyridine derivative having an excellent pharmacological activity. This invention provides a novel dihydropyridine derivative (I) represented by the general formula wherein R₁ and R₂ are the same as or different from each other and are each, independently of one another, hydrogen, provided that they cannot be hydrogen at the same time, or a nitro, cyano, halogen, C₁₋₆ alkyl, halogenated C₁₋₆ alkyl, C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy, C₁₋₆ alkylmercapto, C₁₋₆ alkylsulfinyl or C₁₋₆ alkylsulfonyl; R₃, R₄ and R₅ are each, independently of one another,C₁₋₆ alkyl; R₆ and R₇ are each, independently of one another, hydrogen, C₁₋₆ alkyl or ar C₁₋₃ alkyl, which alkyl or aralkyl is optionally substituted by halogen; X denotes a group -COO-; and A denotes an alkylene group; and an innoxious salt thereof. Compounds embodying the present invention, hereinafter "the present compounds" have an excellent Ca-antagonistic activity, antihypertensive effect, thrombocyte agglutination inhibition effect and phosphodiesterase inhibition effect and are useful as medicines, for example as a coronary vessel vasodilator, cerebral blood flow increasing agent, antihypertensive agent, preventive or curative agent for thrombosis, and phosphodiesterase inhibitor. Additionally, this invention provides a pharmaceutical composition useful for treating vascular disorders such as coronary and cerebral artery diseases comprising at least one dihydropyridine derivative (I) or innoxious salt thereof. The dihydropyridine derivative (I) of this invention has a unique structure as compared with the prior dihydropyridine compounds known in the art and hence has a unique activity originating from the structure. Thus, it is expected that the dihydropyridine derivative (I) of this invention has a high organ and tissue selectivity, particularly in vasodilating action, and hence can attain an excellent pharmacological effect at a relatively small dose. As a result, it is characterized by its reduced systemic side effects. In the present specification, halogen or halogenated means fluorine, chlorine, bromine or iodine, or their substituent. Preferably, it is fluorine, chlorine, or bromine, and preferably fluorine or bromine for R₁ and R₂. Alkyl may be either of straight chain or branched chain and includes, for example, alkyls of 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl and preferably methyl for R₃, R₄, and R₅. Aralkyl groups include the phenyl C₁-C₃ alkyl group, for example, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-phenylpropyl and 1-phenylpropyl, the said phenylgroup being optionally substituted with substituent(s) such as an alkyl or halogen, among which benzyl is preferred for R₆ or R₇. Alkylene groups have preferably 2 to 4 carbon atoms, may be either of straight chain or branched chain and include, for example, ethylene, trimethylene, propylene, tetramethylene, and 1,2-dimethylethylene group, and preferably an ethylene group. In the present specification, the alkyl moiety and halogen in the alkoxy, halogenated alkyl, alkylmercapto, alkylsulfinyl, and alkylsulfonyl group for R₁ or R₂ are the same as the above-defined alkyl and halogen. The halogenated alkyl may be those in which a proportion of their hydrogen atoms have been halogenated [(CF₃)₂CHCH₂-, CF₃CH₂- etc.] or those in which all of the hydrogen atoms have been halogenated (trifluoromethyl etc.), and trifluoromethyl is preferable for R₁ or R₂. Also, the halogenated alkoxy may be either those in which a proportion of their hydrogen atoms have been halogenated or those in which all of the hydrogen atoms have been halogenated. In the general formula (I), the position of pyridyl group to be connected at the 4-position of the dihydropyridine is preferably the 2-, 3-, or 4-position thereof; and the position of the substituent R₁ or R₂, which are not hydrogen, may preferably be at a position next or next but one to the bond site of the pyridyl group with the dihydropyridyl group. Further, the relative positions of the R₁ and the R₂ when both are present, are next, next but one or next but two to each other. The dihydropyridine derivative (I) can be prepared by reacting an optional part constituting the dihydropyridine derivative (I) with the remaining part of the derivative by a method known per se, particularly by subjecting it to dehydrating cyclization. For example, it can be prepared as follows. Method of preparation (A) In the above formulae R₁, R₂, R₃, R₄, R₅, R₆, R₇, X and A are as defined above. Method of preparation (B) In the above formulae R₁, R₂, R₃, R₄, R₅, R₆, R₇, X and A are as defined above. Preferred procedures for carrying out each of the above-mentioned methods of preparation will be described in detail below. Method of preparation (A) In this method, the compounds (II), (III) and (IV) are first reacted in an appropriate solvent to prepare the compound (V). This reaction is carried out usually at about 30°C to 150°C, preferably about 50°C to 120°C, and particularly when the solvent used boils in the above-mentioned temperature range, at the boiling point. The solvent to be used is not particularly limited so long as it is inert to the reaction and includes, for example, alcohols such as methanol, ethanol, propanol, and isopropanol; ethers such as tetrahydrofuran, dioxane, and dimethoxyethane; N,N-dimethylformamide, dimethylsulfoxide, and acetonitrile. The reaction usually requires 1 to 20 hours for completion. As to the amount of the compounds (II), (III) and (IV) to be used, for 1 mole of any one of the three compounds 1 to 1.5 moles of each of the other two compounds is used. The starting compound (II) is already known or can be prepared by a known method [cf., for example, J, Am. Chem. Soc., 67 , 1017 (1945)]. The compound (IV) in already known or can be prepared by a known method [cf., for example, Chem. Pharm. Bull., 27 (6), 1426 (1979)]. The various substituted pyridine aldehydes (III) can be obtained by preparing the pyridine alcohol shown below by a known method and then oxidizing it with, for example, dimethylsulfoxide (DMSO) - dicyclohexylcarbodiimide (DCC) - phosphoric acid. The compound (V) thus obtained is then treated with a secondary amine of the formula HN (R₆) (R₇) (R₆ and R₇ are the same as above) to give the dihydropyridine derivative (I). This reaction is carried out usually at about 50°C to 130°C, preferably at about 70°C to 110°c. Examples of preferred solvents to be used include toluene and N,N-dimethylformamide. The reaction is usually carried out by using 2 to 2.5 moles of the secondary amine relative to 1 mole of the compound (V). The reaction usually requires 1 to 20 hours for completion. Method of preparation B This method can be effected under substantially the same conditions as in the method A. The starting compound (VI) to be used in this method can be prepared by treating the starting compound (IV) used in the method A with the said secondary amine. Thus, it is easily prepared by dissolving the compound (IV) in a suitable solvent (for example, ethanol, dioxane, tetrahydrofuran, N,N-dimethylformamide), then adding to the solution the solution of about 2.5 equivalents of the secondary amine of the formula and allowing the mixture to react at about 30°C to 110°C for 1 to 18 hours. The novel dihydropyridine derivative (I) thus prepared can be recovered by optional means of separation and purification, for example, concentration, extraction, chromatography, reprecipitation and recrystallization, to collect a product of the desired purity. Further, since the dihydropyridine derivative (I) has a basic group, it can also be converted to an acid addition salt by a conventional method. Such acid addition salts are not particularly limited so long as they are pharmaceutically acceptable and innoxious, and include, for example, inorganic acid salts (such as hydrochloride, hydrobromide, phosphate and sulfate) and organic acid salts (such as acetate, succinate, maleate, fumarate, malonate and tartrate). The compounds having simultaneously a hydrogen atom for R₁ and R₂ are not sufficient in their activity, and the preferable compounds of the invention are exemplified as follows: (1) 2,6-Dimethyl-4-(3-nitro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (2) 2,6-Dimethyl-4-(4-bromo-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (3) 2,6-Dimethyl-4-(4-cyano-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (4) 2,6-Dimethyl-4-(4-trifluoromethy-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (5) 2,6-Dimethyl-4-(4-nitro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (6) 2,6-Dimethyl-4-(6-bromo-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (7) 2,6-Dimethyl-4-(6-chloro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (8) 2,6-Dimethyl-4-(6-cyano-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (9) 2,6-Dimethyl-4-(6-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (10) 2,6-Dimethyl-4-(6-nitro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (11) 2,6-Dimethyl-4-(2-bromo-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester. (12) 2,6-Dimethyl-4-(2-cyano-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (13) 2,6-Dimethyl-4-(2-trifluoromethyl-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (14) 2,6-Dimethyl-4-(5-bromo-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (15) 2,6-Dimethyl-4-(6-cyano-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (16) 2,6-Dimethyl-4-(2-fluoro-4-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (17) 2,6-Dimethyl-4-(5-trifluoromethyl-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl enter 5-methyl ester. (18) 2,6-Dimethyl-4-(5-nitro-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (19) 2,6-Dimethyl-4-(2-cyano-4-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. (20) 2,6-Dimethyl-4-(3-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. The dihydropyridine derivative (I) and its innoxious salt according to this invention are of low toxicity, exert a strong and long-lasting blood pressure depressing action, peripheral blood vessel vasodilating action, coronary artery vasodilating action and cerebral blood vessel vasodilating action on mammals such as mice, rats, rabbits, dogs, cats, and humans, and are useful as, for example, a preventive or curative agent for diseases of circulatory systems in humans, for example, hypertension, ischemic cardiac diseases (e.g. angina pectoris and myocardial infarction), and cerebral and peripheral circulatory disorders (e.g. cerebral infarction and transient cerebral ischemic attack). Particularly, they are excellent in both the intensity and/or the duration of their pharmacological effect as compared with dihydropyridine derivatives of the prior art (for example Nifedipine and Nicardipine) and hence, when used as a preventive or curative agent for hypertension for example, can give a stable depression effect after a fewer number of times of administration (1 to 2 times per day). When the dihydropyridine derivative (I) or its innoxious salt are used as the above-mentioned medicaments, they can be mixed with such pharmaceutically necessary ingredients as appropriate, pharmaceutically compatible carriers, additives, and diluents and made up into pharmaceutical compositions in the form of powders, granules, tablets, capsules, and injectable compositions, to be administered orally or parenterally. The above-mentioned pharmaceutical preparations contain an effective amount of the dihydropyridine derivative (I) incorporated therein. The dosage varies depending upon the route of administration, the conditions, weight or age of patients, and other factors. For oral administration to adult hypertension patients for example, it is preferably administered at a dose of 0.05 to 20 mg/kg body weight/day, more preferably 0.1 to 4 mg/kg body weight/day, divided in 1 to several times per day. The results of pharmacological tests conducted to show the effectiveness of the dihydropyridine derivative (I) and its innoxious salt of this invention are described below. The results (LD₅₀) of acute toxicity test of the present Ca-antagonist (P.O.) in mice are 650-950 mg/kg. Blood pressure depression effect Test 1 Male, spontaneously hypertension-developing rats of ages of 10 to 11 weeks (in groups of 3 to 5 animals) were used in the test. For blood pressure determination, systolic pressure was measured without anesthesia by an indirect tail-cuff method using a sphygmomanometer (PE-300, Narco Bio-System). The compound to be tested was orally administered (at a dose of 25 mg/kg in terms of the active compound) as a 10% HCO-60 (polyoxyethylene hardened castor oil) suspension. Blood pressure was determined 1, 4 and 7 hours after the administration. Table 1 shows the respective average value of the blood pressure (in mmHg). Further, the blood pressure depression effect of the fumarate of the compound obtained in Example 28 described later was examined in the same manner as described above. The result obtained showed that the value (100%) before administration was 67%, and the time required for 50% recovery from maximum depression value (%) of blood pressure was 16.2 hours. Test 2 The above Test 1 was repeated with respect to various compounds of the invention as well as Nicardipine and Nifedipine, including the compounds in Table 1, except that the time after the administration was prolonged to 24 hours, and the blood pressure lowering maximum and the duration until the pressure recovered to 50% from the maximum depression value (%) of blood pressure were measured. The results are shown as in Table 2, the changes of blood pressure being expressed as per cent based on that before administration. This invention will be explained in more detail below with reference to Examples. Example 1 (1) 2,6-Dimethyl-4-(6-cyano-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-chloroethyl ester 5-methyl ester 6-Cyano-2-pyridine aldehyde (1.613 g, 12.2 mmol), chloroethyl acetoacetate (2.009 g, 12.2 mmol) and methyl 3-aminocrotonate (1.364 g, 12.2 mmol) were dissolved in 16 ml of isopropanol, and the solution was stirred at 35 to 40°C under a nitrogen gas stream for 14 hours. The reaction solvent was distilled off under reduced pressure, and the residue was purified by column chromatography [silica gel; ethyl acetate-n-hexane (5 : 6)]. The crude product thus obtained was recrystallized from isopropyl ether-methanol to obtain 1.546 g (34% yield) of the above-captioned compound. (2) 2,6-Dimethyl-4-(6-cyano-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl enter 5-methyl ester. The chloroethyl ester compound (1.546 g, 4.11 mmol) obtained in (1) and N-methyl-N-benzylamine (1.047 g, 8.64 mmol) were dissolved in 12 ml of N,N-dimethylformamide, and the solution wan stirred at 100 to 105°C under a nitrogen gas stream for 11.5 hours. The reaction solvent was distilled off under reduced pressure. The resulting residue was mixed with water and extracted with diethyl ether. The diethyl ether layer was washed with water, dried, and then the solvent was distilled off under reduced pressure. The residue was purified by column chromatography [silica gel; ethyl acetate-n-hexane (3 : 1)]. Thus, 449 mg (29% yield) of the starting material was recovered as the first fraction, and then 929 mg of the crude desired compound was obtained as the second fraction. The crude product was further purified by column chromatography [silica gel; chloroform - methanol (96 : 4)] to obtain 882 mg (47% yield) of the desired compound. Example 2 The final compound obtained in Example 1 (858 mg, 1.86 mmol) and fumaric acid (216 mg, 1.86 mmol) were dissolved in 25 ml of ethanol, and the solution was stirred at room temperature for 70 minutes. The reaction solvent was distilled off under reduced pressure to obtain 1.07 g of the fumaric acid salt of the compound. Example 3 (1) 2,6-Dimethyl-4-(6-bromo-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-chloroethyl ester 5-methyl ester. A solution of 6-bromo-2-pyridine aldehyde (1.542 g, 8.29 mmol), chloroethyl acetoacetate (1.388 g, 8.43 mmol) and methyl 3-aminocrotonate (948 mg, 8.29 mmol) in 12 ml of isopropanol was stirred under a nitrogen gas stream, at 40°C for 9 hours and at room temperature for 13 hours. The reaction solvent was distilled off under reduced pressure, and the residue was purified by column chromatography [silica gel; ethyl acetate-n-hexane (2 : 3)]. The crude product thus obtained was recrystallized from isopropyl ether-methanol to obtain 1.730 g (49% yield) of the above-captioned compound (m.p. 152 to 153°C). (2) 2,6-Dimethyl-4-(6-bromo-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. The chloroethyl ester compound (1.509 g, 3.51 mmol) obtained in (1) and N-methyl-N-benzylamine (894 mg, 7.37 mmol) were dissolved in 11 ml of N,N-dimethylformamide, and the solution was stirred at 100 to 105°C under a nitrogen gas stream for 15.5 hours. The reaction solvent was distilled off under reduced pressure. The residue was mixed with water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried, and then the solvent was distilled off under reduced pressure. The residue was purified by column chromatography [silica gel; ethyl acetate-n-hexane (5 : 2)]. The crude product thus obtained was recrystallized from isopropyl ether-methanol to obtain 1.141 g (63% yield) of the desired compound. M.p.: 123.5 to 124.5°C. Example 4 The final compound (1.037 g, 2.02 mmol) obtained in Example 3 and fumaric acid (234 mg, 2.02 mmol) were dissolved in 24 ml of ethanol, and the solution was stirred at room temperature for 4 hours. The reaction solvent was distilled off under reduced pressure to obtain 1.2 g of the fumaric acid salt of the compound. Example 5 2,6-Dimethyl-4-(4-nitro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. The same procedure as that described in Example 1 was followed except for using 4-nitro-2-pyridine aldehyde in place of 6-cyano-2-pyridine aldehyde to obtain the compound in 25% yield (m.p.: 163°C, methanol). Example 6 2,6-Dimethyl-4-(2-trifluoromethyl-4-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. The same procedure as that described in Example 3 was followed, except for using 2-trifluoromethyl-4-pyridine aldehyde in place of 6-bromo-2-pyridine aldehyde to obtain the above desired compound in the form of oil (55% yield). Examples 7 to 39 The compounds shown in Tables 3 to 6 were obtained in the same manner as in any one of Examples 1 to 6. Some of the compounds obtained in Examples 7 to 39 can be identified by means of nuclear magnetic resonance and others, as shown in Table 7. The above ingredients were mixed with starch to obtain 300 mg of a tablet preparation, according to a conventional tablet preparation method.

Claims: A dihydropyridine derivative of the formula wherein R₁ and R₂ are the same as or different from each other and are each, independently of one another, hydrogen, provided that they cannot be hydrogen at the same time, or nitro, cyano, halogen, C₁-C₆ alkyl, halogentated C₁₋₆ alkyl, C₁₋₆ alkoxy, halogenated C₁₋₆ alkoxy, C₁₋₆ alkylmercapto, C₁₋C₆ alkylsulfinyl or C₁-C₆ alkylsulfonyl; R₃, R₄ and R₅ are each, independently of one another, a C₁-C₆ alkyl; R₆ and R₇ are each, independently of one another, hydrogen or a C₁-C₆ alkyl or arC₁-C₃ alkyl of which said alkyl or aralkyl hydrogen may be optionally substituted by halogen; X denotes a group -COO-; and A denotes a C₂-C₄ alkylene group, or an innoxious salt thereof. A dihydropyridine derivative of Claim 1, wherein the derivative has the formula, wherein R'₁ denotes methyl, chlorine, bromine, fluorine, trifluoromethyl, nitro, cyano or methoxy, R'₇ denotes benzyl; and the dihydropyridine links to the 2-, 3-, or 4-position of the pyridine. A dihydropyridine derivative of Claim 2, which is 2,6-dimethyl-4-(3-nitro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(4-bromo-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(4-cyano-2-pyridyl)-1,4-dihydropyrdine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(6-cyano-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(4-nitro-2-pyridyl)-1,4-dihydropyridine- 3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(6-bromo-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4,(6-chloro-2-pyridyl]) - 1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(6-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(4-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(2-bromo-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(2-cyano-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(2-trifluoromethyl-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(5-bromo-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(6-cyano-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(6-nitro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(5-nitro-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(5-trifluoromethyl-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, 2,6-dimethyl-4-(2-cyano-4-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester, or 2,6-dimethyl-4-(3-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester. A process for producing a dihydropyridine derivative of the formula (I) or innoxious salt thereof of Claim 1, characterized in that three compounds of the formulae and R₄COCH₂X-ACl or are reacted with one another to form a compound of the formula or the compound of the formula (I), and when the compound of the formula (II) is obtained the compound is reacted with a secondary amine of the formula wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, X and A are same as defined in claim 1; and optionally reacting the thus formed compound of formula (I) with an innoxious inorganic or organic acid. A pharmaceutical composition useful for treating vascular disorders comprising at least one dihydropyridine derivative or innoxious salt thereof of claim 1, and a diluent.

Inventors: ASHIMORI, ATSUYUKI, FUKAYA, CHIKARA, ONO, TAIZO HAITSU HIGASHIYAMA 22, YOKOYAMA, KAZAMASA
Applicants: GREEN CROSS CORPORATION
Application year: 1986
Main classification: C07D401
IPC codes: C07D401, C07D521